Research Article

Efficiency of Intranasal Fentanyl in Patients with Breakthrough Cancer Pain in Daily Practice - Results of the German Non-Interventional Study with Instanyl® (GENISIS)

Published On: October 15, 2014 | Pages: 016 - 027

Author(s): Michael A Ueberall*, Bernd-Oliver Maier, Thomas Nolte

Objective: Breakthrough cancer pain (BTcP) affects 19-95% of cancer patients (dependent on the definition and methods used and the populations studied) and is associated with detrimental physical, psychological and social complications in affected individuals as well as with significant economic burden on society and the healthcare system. This study evaluated the ana ...

Review Article

Spinal Anesthesia for Laparoscopic Cholecystectomy

Published On: July 23, 2014 | Pages: 001 - 008

Author(s): Luiz Eduardo Imbelloni*

In 1985, the first laparoscopic cholecystectomy was performed, and the introduction of laparoscopic cholecystectomy proved to be a new era in the management of cholelithiasis. In his only start, only patients who were good surgical risks, with non acute disease and no prior abdominal surgeries were selected for the procedure. However, as experience was gained, the poo ...

Case Report
Severe Repeated Hypotension Occurred after Rocuronium Administrations in a Morbidly Obese Patient: A Case Report

Published On: September 06, 2014 | Pages: 013 - 015

Author(s): Fabio Silvio Mario Araimo Morselli*, Paolo Tordiglione, Ilaria Scarpa, Francesco Zuccarini, Giovanni Rosa

Rocuronium pharmacokinetics and pharmacodynamics can be influenced by several factors like gender and obesity. We propose a brief report of a patient (59 years old, weight 135 kg, BMI 52.7) who showed three episodes of severe hypotension not responsive to continuous noradrenaline infusion therapy after rocuronium administration (dose 0.6 mg/kg; total dose: 50 mg) not ...
Author(s): Adam M Kaye

Physicians employed in operating and emergency rooms have utilized opioid antagonist for almost half a century for the treatment of opioid overdose. The prototype antagonist remains naloxone hydrochloride, which actually received FDA approval back in 1971. Why after so many years on the market is this medication now being formulated in the form of an easy to use "auto ...